To define MMP-persistence, a group was created with the researchers who defined five weighted items according to the importance agreed.The variables collected were sex, age, social/work situation, comorbidities, substances consumption, methadone treatment (doses, frequency, duration, number of dropouts/interruptions since the MMP onset). MRCI score and MMP-persistence were calculated. They were collected and managed using REDCap. Statistical analysis was carried out using SPSS ® Statistics (v.27).The study was approved by the Ethics Committee. Results 84 patients signed the informed consent. 79.8% were male (median age:51(46-56)). 25.4% had a job and 14.9% was homeless. 57.0% had any comorbidity. 62.5% had infectious disease and almost 40% mental health disorder.Substances consumption was tobacco (81.4%), benzodiazepines (74.0%), cocaine (65.0%), alcohol (42.4%), heroin (33.9%) and cannabis (28.3%). 2.9% were intravenous-drugusers (IVDU). Median methadone dose was 60mg (40-80). 63.1% received maintenance doses. 38.1% received methadone for>10 years. None of the patients abandoned MMP at any time.The median MRCI score was 13.5 (8.5-21.8) (maximum:40.5).Regarding MMP-persistence, a patient was considered persistent with a score !90% according to our definition. We found 77.4% persistent patients.No association was found between MRCI and MMP-persistence (p=0.74). However, the following variables had relationship: age (p=0.04), comorbidity (0.002) and patients receiving maintenance doses (p=0.024).Regarding MRCI, we found association with age (p=0.04), homeless (p=0.002), comorbidity (p=0.0), HBV (p=0.003), mental health disorder (p=0.006), active heroin consumption (p=0.03) and IVDU(p=0.03). Conclusion and RelevanceA new MMP-persistence definition has been created. We identified age, comorbidities, and receiving methadone maintenance doses as successful predictors for MMP-persistence.MRCI does not seem to be a useful tool to determine the MMP-persistence, probably because there are multiple factors that influence in addition to the CPR. It is necessary to continue searching for more precise selection and stratification tools for ODP to improve their persistence. However, it should not be an obstacle to implementing measures to optimise their pharmacotherapy.

methods A cross-sectional study in the Paediatrics Emergency Care Unit was used as pilot test. The day the study was completed, the relation of registered children in the unit was obtained via an informatic program. Both demographic (age and weight) and clinical (symptomatology, complementary tests, diagnosis and discharge treatment) were registered. For each patient, adequacy of the prescribed antibiotic, indication and dose adjustment to weight and age, were analysed. Results From the 114 assessed patients, 16 (14%) were treated with antibiotics and recruited for follow-up. The most common diagnosis was tonsillitis (25%), acute bronchitis (19%) and otitis media (19%), being the remaining percentage cases of appendicitis, urinary tract infections, nasopharyngitis, cellulitis and laryngitis. From the 16 prescribed treatments, 12 were susceptible of recommendation.The main identified causes for treatment modification were an excessive duration (50%), an inadequate dose for either shortage (25%) or excess (8%) or a suboptimal antibiotic choice (17%). Conclusion and relevanceResults showed a low adequacy of the antibiotic treatments, thus evidencing the need for a PROA that improves the prescription quality and guarantees patient safety. Members from the PROA group must ensure education about antibiotics prescription, emphasising the features of children as a population group and sharing the local antibiotic guide from the hospital.

was >90% for both infusions at 0.5 and 3 hours. For tazobactam, the PTA fT >70% MIC for a ClCr=70 mL/min for the doses 0.5 g/8 hours and 0.5 g/6 hours were 56% and 89%, increasing in the extended infusion of 3 hours (87% and 98%). For a ClCr >120 mL/min, this probability was significantly reduced, being <50% for the dose 0.5 g/8 hours in a 0.5 hour infusion. Conclusion and relevance The pharmacokinetic/pharmacodynamic objective of fT >100% MIC for piperacillin/tazobactam required a dose of 4/0.5 g/6 hours or extended infusion, especially in patients with high renal clearance and in strains with high levels of expression of beta-lactamases. REFERENCES AND/OR ACKNOWLEDGEMENTS No conflict of interest.